The mechanisms by which dysfunctional glial cells contribute to ALS have remained poorly defined. Now, Harvard University researchers have identified a therapeutic target-prostaglandin D2 receptor subtype DP1-and shown that reducing its expression can prolong survival in a mouse model of ALS.